TickerKhojPharmaceuticals · Pharmaceuticals: Major · NSE: SAKAR · data 2026-11-02
Sakar Healthcare Ltd
In plain words
Price: 24.4% below its 52-week high of ₹1,229.85.
Delivery: 40.3% of traded shares were kept for delivery over the last 10 sessions, against 46.6% over the last 60.
Latest results: a net profit of ₹11 cr for the quarter ended Sept 2026 (+149.1% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹302 cr |
| Net profit (last 12 months) | ₹43 cr |
| Sales growth, 3 years (yearly) | 23.6% |
| Profit growth, 3 years (yearly) | 33.7% |
At a glance
Promoters 51.7% (-1.2 pts in a year), pledged 0.0%, institutions 24.3%.
P/E 48.2, P/B 6.0, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 10.0%, ROCE 12.4%, operating margin 21.5%: how much profit it earns on the money it uses.
Debt/equity 0.17, Profit growth 33.7% and sales growth 23.6% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Healthy operating margin (21.5%).
- Profit grew 33.7% a year over 3 years.
- Promoters cut their holding by 1.2 points in a year.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
SAKAR Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹87.42 crore, up 51.9% YoY and up 19.8% QoQ.
Net profit was ₹11.31 crore, up 149.1% YoY and up 10% QoQ.
Operating margin was 27.8% (19.7% a year ago).
EPS was ₹5.08, up 150.2% YoY and up 10% QoQ.
SAKAR के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹87.42 करोड़; पिछले साल की तुलना में 51.9% की बढ़त, पिछली तिमाही की तुलना में 19.8% की बढ़त।
शुद्ध मुनाफ़ा: ₹11.31 करोड़; पिछले साल की तुलना में 149.1% की बढ़त, पिछली तिमाही की तुलना में 10% की बढ़त।
ऑपरेटिंग मार्जिन: 27.8% (एक साल पहले 19.7%)।
EPS: ₹5.08; पिछले साल की तुलना में 150.2% की बढ़त, पिछली तिमाही की तुलना में 10% की बढ़त।
SAKARના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹87.42 કરોડ; ગયા વર્ષની સરખામણીએ 51.9% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 19.8% વધારો.
ચોખ્ખો નફો: ₹11.31 કરોડ; ગયા વર્ષની સરખામણીએ 149.1% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 10% વધારો.
ઓપરેટિંગ માર્જિન: 27.8% (એક વર્ષ પહેલાં 19.7%).
EPS: ₹5.08; ગયા વર્ષની સરખામણીએ 150.2% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 10% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-11-02
- Delivery vs usual 0/30: Delivery 38.8% over the last 20 sessions vs 40.4% in the 40 before (0.96x); shares delivered per day 1.01x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results
- 23 Oct 26Results Q2 FY27 results: profit +149.1% YoY +2.0% next session
- 24 Jul 26Results Q1 FY27 results: profit +120.1% YoY +0.3% next session
- 12 May 26Results Q4 FY26 results: profit +91.3% YoY +13.2% next session
- 5 Feb 26Results Q3 FY26 results: profit +126.3% YoY +6.7% next session
- 7 Nov 25Results Q2 FY26 results: profit −5.4% YoY +1.5% next session
- 25 Jul 25Results Q1 FY26 results: profit +93.8% YoY -4.2% next session
- 16 May 25Results Q4 FY25 results: profit +84.6% YoY -2.4% next session
- 8 Feb 25Results Q3 FY25 results: profit +118.8% YoY -5.2% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹87 cr | ₹11 cr | +149.1% | 27.8% | 5.08 |
| Jun 2026 | ₹73 cr | ₹10 cr | +120.1% | 29.1% | 4.62 |
| Mar 2026 | ₹71 cr | ₹11 cr | +91.3% | 36.9% | 4.96 |
| Dec 2025 | ₹70 cr | ₹10 cr | +126.3% | 26.4% | 4.59 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 51.70% | 52.52% | 52.86% | 52.86% |
| Foreign institutions (FII) | 12.34% | 12.13% | 12.94% | 13.05% |
| Domestic institutions (DII) | 11.92% | 11.37% | 11.32% | 11.36% |
| Mutual funds | — | — | — | — |
| Retail investors | 17.09% | 16.06% | 12.49% | 10.90% |
| Number of shareholders | 19,539 | 14,734 | 9,580 | 7,069 |
Common questions
What was Sakar Healthcare Ltd's latest quarterly profit?
Sakar Healthcare Ltd reported a net profit of ₹11 cr for the quarter ended Sept 2026 (+149.1% on the same quarter a year earlier), on revenue of ₹87 cr.
How much do promoters hold in Sakar Healthcare Ltd?
Promoters held 51.70% of Sakar Healthcare Ltd at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Sakar Healthcare Ltd debt-free?
Its latest reported debt-to-equity ratio is 0.17.
What is Sakar Healthcare Ltd's P/E ratio?
About 48.2, based on the last 12 months' earnings and a price of ₹929.45 (data 2026-11-02).
What is the 52-week high and low of Sakar Healthcare Ltd?
The 52-week high is ₹1,229.85 and the 52-week low is ₹352.5.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Sakar Healthcare Ltd | ₹929.45 | ₹2,074 cr | 48.2 | 6 | 10% | 12.4% | 0.17 | +158.0% |
| Alembic Limited | ₹89.89 | ₹2,239 cr | 7.2 | — | 13.3% | 3.3% | 0 | -10.5% |
| Beta Drugs Ltd. | ₹1,765.5 | ₹2,000 cr | 36.2 | 4.5 | 18.8% | 16.6% | 0.62 | -2.5% |
| Hester Biosciences Limited | ₹2,302.5 | ₹1,956 cr | 14.4 | — | 16.5% | 13% | 0.54 | +43.7% |
| Indoco Remedies Limited | ₹213.6 | ₹1,923 cr | 61.6 | 1.9 | -9.7% | -2% | 1.15 | -24.0% |
| Panacea Biotec Limited | ₹321.9 | ₹1,917 cr | — | — | -0.6% | -6.3% | 0.03 | -27.1% |
Compare SAKAR with ALEMBICLTD in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SAKAR in TickerKhoj →